in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at PharmStar, Cephalon, Covidien and Catalent.
Howard Phykitt has been named chairman and CEO of PharmStar Pharmaceuticals. Phykitt has previously worked on development of granulation and coating technology, as well as fluid bed micro-encapsulation.
Cephalon has appointed Charles Homcy to its board of directors. Homcy is a venture partner at Third Rock Ventures and co-chairman of Portola Pharmaceuticals. Earlier in his career Homcy worked at COR Therapeutics and Millennium Pharmaceuticals.
Jose Almeida is to succeed Richard Meelia as president and CEO of Covidien on July 1. Almeida will serve as non-executive chairman for a transition period of up to one year. Almeida is currently president of the medical device unit at Covidien.
Catalent Pharma Solutions has appointed Tim McFadden as vice president (VP) of consumer health softgel. McFadden worked at Wyeth, and later Pfizer, for 19 years before joining Cardinal Health.
Ann Daus has joined Laureate Biopharmaceutical as VP, quality. Daus has previously held quality-related positions at ImClone, SmithKline Beecham and Johnson & Johnson (J&J).
Enzon Pharmaceuticals has appointed Richard Mulligan as vice chairman of its board of directors. Mulligan, who joined the board in 2009, is the Mallinckrodt Professor of Genetics at Harvard Medical School and Director of the Harvard Gene Therapy Initiative.
Julia Dishman has been hired as manger, sales and marketing at BioProcess Technology Consultants (BPTC). Dishman last worked as an independent consultant, for BPTC and other companies, and has also held positions at Merrimack Pharmaceuticals.
Pharmaceutics International Inc (PII) has named Rampurna Prasad Gullapalli as VP of drug delivery technologies. Gullapalli joins from Elan Pharmaceuticals and has also worked at Chiron, Purdue Pharma and Banner Pharmacaps.